2024-11-08T10:14:42-06:00 2023-12-31 814234542 BPM LLP 2001 NORTH MAIN STREET SUITE 360 WALNUT CREEK CA 945967253 990 2023-01-01 264443340 MEDICINES360 MEDI 4159518700 49 STEVENSON STREET 1100 SAN FRANCISCO CA 94105 BRADLEY LUKE CFO 4159518700 2024-11-06 1 0 ELENA P SEREBRIAKOVA P01382840 9252961040 2024-11-06 2023 2024-10-15 13:58:12Z ANDREA OLARIU 49 STEVENSON STREET 1100 SAN FRANCISCO CA 94105 41470077 0 X HTTP://WWW.MEDICINES360.ORG X 2009 CA MEDICINES360 IS A NON-PROFIT PHARMACEUTICAL ORGANIZATION THAT ADDRESSES UNMET NEEDS OF WOMEN BY DEVELOPING INNOVATIVE, AFFORDABLE AND SUSTAINABLE MEDICINES AND DEVICES 7 6 46 0 0 0 481076 854099 0 0 132747 -6717 10320098 9159360 10933921 10006742 3196 43735 0 0 10173609 10608675 0 0 747085 8561974 8674087 18738779 19326497 -7804858 -9319755 65028349 51992405 5787561 5160104 59240788 46832301 MEDICINES360 IS A NON-PROFIT PHARMACEUTICAL ORGANIZATION THAT ADDRESSES UNMET NEEDS OF WOMEN BY DEVELOPING INNOVATIVE, AFFORDABLE AND SUSTAINABLE MEDICINES AND DEVICES 0 0 13832521 43735 240035 THE ORGANIZATION RECEIVED NDA APPROVAL FOR ITS IUD PRODUCT LILETTA IN 2015. LILETTA HAS BEEN DISTRIBUTED THROUGH MEDICINES360'S COMMERCIAL PARTNER SINCE APRIL 2015. THE ORGANIZATION CONTINUED CLINICAL TRIALS BEYOND THE INITIAL APPROVAL FOR THE PRODUCT. IN ADDITION, THE ORGANIZATION CONTINUES DEVELOPING CERTAIN MEDICAL PRODUCTS RELATING TO WOMEN'S REPRODUCTIVE HEALTH AND WORKS TO EXPAND ACCESS TO ALL WOMEN IN NEED. 13832521 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 53 0 1 46 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X NATALIE OTTEN 4159518700 49 STEVENSON STREET SUITE 1100 SAN FRANCISCO CA 94105 TINA RAINE-BENNET CEO THRU 5/16/23 40.00 0.00 X X 1167104 0 45093 LESLIE BENET CHAIR 2.00 0.00 X 60000 0 0 LISA DAVID DIRECTOR 2.00 0.00 X 40000 0 0 KAREN DAWES DIRECTOR 2.00 0.00 X 40000 0 0 ANN BARBER DIRECTOR 2.00 0.00 X 40000 0 0 MIKE DORSEY DIRECTOR 2.00 0.00 X 40000 0 0 ELIZABETH GARNER DIRECTOR 2.00 0.00 X 40000 0 0 ANDREA I OLARIU COO THRU 5/15/23, CEO FROM 5/16/23 34.46 5.54 X X 540078 176148 270356 BRADLEY LUKE CHIEF FINANCIAL OFFICER 34.20 5.80 X 411443 82439 146980 ETHAN K KNOWLDEN GENERAL COUNSEL/BOD SEC THRU 2/28/23 34.20 5.80 X 329840 56087 9973 CYNTHIA HU GENERAL COUNSEL/BOD SEC FROM 8/7/23 34.20 5.80 X 104462 18218 66908 MARK R BUSCH SVP, QA & PRODUCT SAFETY 26.61 13.39 X 266603 181012 132231 ROBERT DECKMAN VP, PRODUCT DEV & SUSTAIN ENG 40.00 0.00 X 365760 0 151109 STACEY MANLEY VP, COMMS & MARKETING THRU 9/30/23 40.00 0.00 X 407402 0 34948 AUTUMN EHNOW EVP, CORPORATE AFFAIRS 19.40 20.60 X 185846 315779 169376 STEPHANIE KURTEFF HEAD OF COMPLIANCE THRU 9/8/23 34.20 5.80 X 299096 51233 26708 4337634 880916 1053682 36 0 1 0 JPA HEALTH COMMUNICATIONS 1101 CONNECTICUT AVENUE NW STE 600 WASHINGTON DC 20036 CONSULTANT SERVICES 599062 ALLUCENT (US) LLC 2000 CENTREGREEN WAY STE 300 CARY NC 27513 CONSULTANT SERVICES 504258 UNIVERSITY OF CALIFORNIA DAVIS PO BOX 989062 WEST SACRAMENTO CA 957989062 CONSULTANT SERVICES 384403 WAXMAN STRATEGIES 4600 ROSWELL ROAD NE - BLDG H UNIT SANDY SPRINGS GA 30342 CONSULTANT SERVICES 284000 PLANET PHARMA GROUP LLC 800 HILLGROVE AVENUE STE 201 WESTERN SPRINGS IL 60558 CONSULTANT SERVICES 276398 15 854099 854099 1781575 1781575 8919325 8919325 29465085 31253377 -1788292 -1788292 -1788292 130770 209958 -79188 -79188 CO-PROMOTIONAL REVENUE 900099 311631 311631 OTHER REVENUE 900099 7592 7592 319223 10006742 240035 0 8912608 X 43735 43735 3047123 1469991 1416660 160472 5995264 4715868 993164 286232 173641 126458 39220 7963 921189 645322 230555 45312 471458 323583 124622 23253 564061 292499 271562 141807 141807 30263 30263 151843 151843 4090779 3364050 646383 80346 849290 849290 602614 413689 159217 29708 521877 358188 137949 25740 383945 263519 101489 18937 198904 136517 52577 9810 817484 561077 216088 40319 MILESTONE PAYMENTS 100000 100000 PAYROLL PROCESS FEE 66416 45584 17556 3276 RECRUITING 46101 31641 12186 2274 EMPLOYEE EVENTS 39131 26857 10344 1930 69572 34390 23669 11513 19326497 13832521 4746891 747085 1633347 811209 1863898 1202424 9981 0 2991062 2473387 0 356789 1039283 941546 2581899 2028919 626666 552980 48005499 42851767 1000 1000 8857613 2801303 65028349 51992405 3408982 3347536 2378579 1812568 5787561 5160104 X 59075817 46041798 164971 790503 59240788 46832301 65028349 51992405 X -9319755 5161567 -8250299 X 0 1 X 1 0 X UNIVERSITY OF CALIFORNIA DAVIS CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 1 500 0 1 34426 0 0 34926 0 PART II-B, LINE 1: MEDICINES360'S POLICY POSITIONS HAVE BEEN ROOTED IN EVIDENCE WITH A FOCUS ON PROVIDING A CORPORATE RESPONSE TO PROTECT AND CONVEY OUR MISSION AS A NON-PROFIT PHARMACEUTICAL ORGANIZATION FOCUSED ON WOMEN'S HEALTH INNOVATION. WE HAVE ACTIVELY ENGAGED WITH FEDERAL AND STATE POLICY MAKERS TO ADVOCATE FOR POLICY CHANGE THAT WOULD IMPROVE THE ABILITY OF A NONPROFIT PHARMACEUTICAL ORGANIZATION TO COMPLETE MISSION WORK. WE HAVE ALSO WORKED TO CONVEY OUR POSITION ON 340B POLICIES, TITLE X AND LARC RELATED AND DRAFT LEGISLATION. WE HAVE ALSO ISSUED MEDIA STATEMENTS ON OUR PRIORITY ISSUES AND PUBLIC COMMENT TO THE RECORD FOR SENATE AND HOUSE HEARINGS ON THESE TOPICS. 231565 91283 140282 1945368 1616845 328523 404966 320791 84175 552980 DEPOSIT 282945 SERP RETIREMENT 357630 RIGHT OF USE ASSETS 1660728 CONVERTIBLE NOTE 500000 2801303 DEFERRED LEASE LIABILITY 1812568 1812568 X PART X, LINE 2: AS OF DECEMBER 31, 2023 AND 2022, THE COMPANY HAD NO UNRECOGNIZED TAX BENEFITS. THE COMPANY DOES NOT EXPECT ANY MATERIAL CHANGES TO ITS UNRECOGNIZED TAX BENEFITS WITHIN THE NEXT TWELVE MONTHS. AS A RESULT, THE COMPANY DID NOT RECOGNIZE INTEREST AND PENALTIES RELATED TO UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSE. 0 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OUTSOURCED SERVICES 67824 EUROPE 0 0 PROGRAM SERVICES INVENTORY RELATED TO AVIBELA SALES 293376 SOUTH ASIA 0 0 PROGRAM SERVICES OUTSOURCED SERVICES 6041 EAST ASIA 0 0 PROGRAM SERVICES OUTSOURCED SERVICES 3224 SUB-SAHARAN AFRICA 0 0 GRANTS 43735 EUROPE 0 0 PROGRAM REVENUE - $84,990 SUB-SAHARAN AFRICA 0 0 PROGRAM REVENUE - $45,780 MIDDLE EAST 0 0 INVESTMENT 500000 0 0 0 0 0 0 914200 0 914200 SUB-SAHARAN AFRICA DONATION OF AVIBELA UNITS 0 17280 AVIBELA UNITS COST SUB-SAHARAN AFRICA DONATION OF AVIBELA UNITS 0 17280 AVIBELA UNITS COST SUB-SAHARAN AFRICA DONATION OF AVIBELA UNITS 0 9175 AVIBELA UNITS COST 1 2 0 0 0 0 0 0 1 X X X X X 1 0 0 0 0 0 0 1 0 TINA RAINE-BENNET CEO THRU 5/16/23 347812 0 814903 0 4389 0 23400 0 21693 0 1212197 0 187200 0 ANDREA I OLARIU COO THRU 5/15/23, CEO FROM 5/16/23 440289 98836 97457 76937 2332 375 233162 4487 28177 4530 801417 185165 97457 76937 AUTUMN EHNOW EVP, CORPORATE AFFAIRS 130329 261116 54646 53739 871 924 58503 62121 23645 25107 267994 403007 54646 53739 BRADLEY LUKE CHIEF FINANCIAL OFFICER 302972 71094 104207 10622 4264 723 114819 19472 10849 1840 537111 103751 104207 10622 MARK R BUSCH SVP, QA & PRODUCT SAFETY 200360 147185 60104 30737 6139 3090 72475 36477 15485 7794 354563 225283 60104 30737 ROBERT DECKMAN VP, PRODUCT DEV & SUSTAIN ENG 286772 0 76281 0 2707 0 94263 0 56846 0 516869 0 76281 0 STACEY MANLEY VP, COMMS & MARKETING THRU 9/30/23 223909 0 181634 0 1859 0 8963 0 25985 0 442350 0 69519 0 ETHAN K KNOWLDEN GENERAL COUNSEL/BOD SEC THRU 2/28/23 51613 55939 277354 0 873 148 2808 476 5719 970 338367 57533 0 0 STEPHANIE KURTEFF HEAD OF COMPLIANCE THRU 9/8/23 160016 50976 137564 0 1516 257 6910 1172 15925 2701 321931 55106 53627 0 CYNTHIA HU GENERAL COUNSEL/BOD SEC FROM 8/7/23 103642 18079 0 0 820 139 42573 7220 14633 2482 161668 27920 0 0 PART I, LINE 7 EMPLOYEES OF MEDICINES360 RECEIVED DISCRETIONARY BONUSES THAT WERE APPROVED BY THE BOARD OF DIRECTORS AND DETERMINED BY THE FOLLOWING: 1. ELIGIBILITY 2. ACHIEVEMENT OF THE MEDICINES360 CONSOLIDATED CORPORATE GOALS 3. ACHIEVEMENT OF THE EMPLOYEE'S INDIVIDUAL GOALS 4. EMPLOYEE'S TARGET BONUS AS A PERCENTAGE OF SALARY AND ALLOCATION OF BONUS BETWEEN MEDICINES360 CONSOLIDATED CORPORATE GOALS AND INDIVIDUAL GOALS FOR THEIR LEVEL. 5. MANAGEMENT AND THE BOARD OF DIRECTORS' DISCRETION PART I, LINE 4A SEVERANCE PAYMENTS DURING 2023 WERE AS FOLLOWS: TINA RAINE BENNETT $627,703, ETHAN KNOWLDEN $277,354, STACEY MANLEY $112,115, AND STEPHANIE KURTEFF $83,937. FORM 990, PART VI, SECTION B, LINE 11B BEFORE FILING, THE TAX RETURN IS PROVIDED TO THE BOARD AUDIT COMMITTEE FOR THEIR REVIEW AND APPROVAL, AND THE FULL BOARD FOR THEIR REVIEW. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS/DIRECTORS ARE REQUIRED TO DISCLOSE OR UPDATE ANNUALLY INTERESTS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE CEO COMPENSATION IS SET ON THE BASIS OF SALARY RANGES FOR COMPARABLY SIZED COMPANIES IN THE RADFORD GLOBAL LIFE SCIENCES SURVEY DATA AND COMPARABLE NON-PROFITS. THE COMPENSATION OF OFFICERS AND KEY EMPLOYEES ARE BENCH-MARKED AGAINST THE RADFORD GLOBAL LIFE SCIENCES SURVEY DATA AND COMPARABLE NON-PROFITS. THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE DATA AND COMPENSATION FOR THE CEO. THE COMPENSATION OF OFFICERS IS REVIEWED AND APPROVED BY THE COMPENSATION COMMITTEE, WHICH IS COMPRISED OF INDEPENDENT BOARD MEMBERS. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONSULTANTS: PROGRAM SERVICE EXPENSES 1,760,010. MANAGEMENT AND GENERAL EXPENSES 183,099. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,943,109. FDA FEES: PROGRAM SERVICE EXPENSES 424,634. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 424,634. OUTSOURCED SERVICES: PROGRAM SERVICE EXPENSES 1,179,406. MANAGEMENT AND GENERAL EXPENSES 463,284. FUNDRAISING EXPENSES 80,346. TOTAL EXPENSES 1,723,036. FORM 990, PART XI, LINE 9: CANCELLATION OF CONVERTIBLE DEBT & CONVERSION TO APIC FOR WHOLLY OWNED SUB -8,250,299. IMPACT RH360 LLC 49 STEVENSON ST SUITE 1150 SAN FRANCISCO CA 94105 MEDICAL PRODUCT DISTRIBUTION CA 130770 428535 MEDICINES360 CURAE PHARMA360 INC 49 STEVENSON ST SUITE 1100 SAN FRANCISCO CA 94105 460978720 MEDICAL PRODUCT SALES & DISTRIBUTION CA MEDICINES360 C 188143 801594 1.00000 1 1 0 0 1 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 CURAE PHARMA360 INC A 579888 ACTUAL CURAE PHARMA360 INC D 4700000 ACTUAL CURAE PHARMA360 INC L 7592 ACTUAL CURAE PHARMA360 INC N 233875 ACTUAL CURAE PHARMA360 INC O 1719610 ACTUAL CURAE PHARMA360 INC Q 2365177 ACTUAL